Successful therapy to a progressive tumor using monoclonal-antibodies to T-cell regulatory molecules and interleukin-2.
Weekly injections of monoclonal antibodies (mAb) to T-cell regulatory molecules, into animals challenged with a progressively growing epithelial cell tumor 3152-PRO, decreased tumor incidence and caused significantly slower tumor growth, compared with animals given identical treatments of control rat mAb. Some of the mAb showed significant synergy with rIL-2 in the successful therapeutic treatment of 3152-PRO. Furthermore, spleen cells from treated mice generated strong tumor-specific cytotoxic activity. The successful elimination of progressively growing 3152-PRO tumor rendered animals specifically resistant to a secondary challenge of 3152-PRO tumor cells, but not to 2237-PRO or 3256-PRO, two other, noncrossreactive tumors.